Sini Li
Overview
Explore the profile of Sini Li including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
264
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Li S, Yong Y, Li Y, Li J, Xie J
J Autism Dev Disord
. 2023 Sep;
54(9):3316-3335.
PMID: 37668850
This review aims to systematically summarize existing evidence to determine the effectiveness of cognitive-based interventions (CBIs) on psychological health and well-being among parents of children with developmental disabilities (DD). Six...
12.
Peng Y, Wang L, Peng L, Liu Q, Yi L, Luo X, et al.
Clin Ther
. 2023 Aug;
45(10):965-972.
PMID: 37537015
Purpose: Trastuzumab deruxtecan has been shown to be effective for advanced breast cancer with low levels of human epidermal growth factor receptor 2. To optimize the allocation of limited health...
13.
Wu M, Qin S, Tan C, Li S, Xie O, Wan X
BMC Med
. 2023 Jul;
21(1):277.
PMID: 37501074
Background: China has one of the highest numbers of liver disease cases in the world, including 6.4 million cirrhosis associated with alcohol-related liver disease (ALD) cases. However, there is still...
14.
Xie J, Li S, Li Y, Li J
BMC Health Serv Res
. 2023 Jun;
23(1):706.
PMID: 37386633
Background: The effectiveness of sacituzumab govitecan for metastatic triple-negative breast cancer (TNBC) has been reported in recent research, however, the value of the effectiveness and cost of sacituzumab govitecan is...
15.
Wang C, Fei K, Liu L, Duan J, Wang Z, Li S, et al.
Thorac Cancer
. 2023 May;
14(19):1843-1856.
PMID: 37221702
Background: Osimertinib is the first-line treatment for patients with epidermal growth factor receptor (EGFR) mutations, but the treatment options after drug resistance are limited. Previous studies have suggested that EGFR...
16.
Wang L, Peng Y, Qin S, Wan X, Zeng X, Li S, et al.
PLoS One
. 2023 Apr;
18(4):e0279786.
PMID: 37053300
Background: Oral multikinase inhibitors and immune checkpoint inhibitors (ICIs) are effective for treating advanced hepatocellular carcinoma (aHCC) but may increase cost. This study compared the cost-effectiveness of oral multikinase inhibitors...
17.
Liu J, Li S, Yan X, Li J, Sun Q, Mei H, et al.
Res Gerontol Nurs
. 2023 Apr;
16(3):147-160.
PMID: 37040310
The current cross-sectional study aimed to investigate social connection and lifestyle factors associated with happiness in urban older adults in mainland China. A total of 709 community-dwelling older adults aged...
18.
Li S, Qu Y, Liu L, Wang C, Yuan L, Bai H, et al.
Cell Prolif
. 2023 Mar;
56(10):e13452.
PMID: 36941028
The liver is a common secondary metastasis site of many malignant tumours, such as the colorectum, pancreas, stomach, breast, prostate, and lung cancer. The clinical management of liver metastases is...
19.
Li S, Liu L, Qu Y, Yuan L, Zhang X, Ma Z, et al.
Int J Mol Sci
. 2023 Mar;
24(5).
PMID: 36901953
The LIM domain family genes play a crucial role in various tumors, including non-small-cell lung cancer (NSCLC). Immunotherapy is one of the most significant treatments for NSCLC, and its effectiveness...
20.
Peng C, Chen J, Cui W, Li S, Li J, Peng L
Front Pharmacol
. 2022 Nov;
13:1037620.
PMID: 36438813
: Given the limitations of Western medicine (WM) for the treatment of non-small cell lung cancer (NSCLC) and the wide exploration of Chinese herbal injections (CHIs), systematically evaluate the efficacy...